58th Annual Aspen Lung Conference

 描述(由申请者提供)：第58届Thomas L.Petty Aspen肺病学年会将聚焦于一个中心问题：我们如何将有关呼吸道免疫学、炎症和修复的机制的知识转化为有效的、个性化的哮喘治疗方法，重点是基础、转换和临床方法的整合？为了解决这一核心问题，我们将该计划组织成一系列主题会议，重点关注(I)哮喘的新概念，包括T细胞生物学、微生物组、巨噬细胞生物学、表观遗传学和氧化剂生物学的新领域；(Ii)宿主反应/固有免疫机制和自噬；(Iii)对机械转导和重塑的当代理解；以及(Iv)将科学进步转化为有效治疗方法的战略方法，包括分子表型、皮质类固醇耐药性和针对轻度、中度和重度哮喘患者的药物开发。通过在六个主题会议上讨论这些主题，我们寻求实现以下目标：1)为领先的基础、翻译和临床研究人员提供一个国际论坛，就导致肺部炎症和重塑的基本概念交换意见。2)促进免疫学、病理学、遗传学和分子生物学等科学领域之间的互动，目的是确定可能导致更有效和更有成效的研究的新的、共同的兴趣。3)通过开发新的战略来更好地将科学进步落实到患者护理中，并通过解决临床试验设计中的挑战，提高将临床前科学进步转化为直接患者利益的成功可能性。4)挑战和激发学员的科学兴趣，吸引新一代初级研究人员进入哮喘病理生物学领域。

 DESCRIPTION (provided by applicant): With an emphasis on the integration of basic, translational and clinical approaches, the 58th annual Thomas L. Petty Aspen Lung Conference will focus on a central question: how can we translate knowledge regarding the mechanisms underlying airway immunology, inflammation and repair into effective, personalized approaches to asthma therapy? To address this central question, we have organized the program into a series of thematic sessions focusing on (i) new concepts in asthma beyond adaptive immunity including new arenas in T cell biology, the microbiome, macrophage biology, epigenetics and oxidant biology, (ii) host response/innate immune mechanisms and autophagy (iii) contemporary understanding of mechanotransduction and remodeling, and (iv) strategic approaches to translating scientific advances into impactful therapy including molecular phenotyping, corticosteroid resistance and drug development for patients with mild, moderate and severe asthma. By addressing these topics across six thematic sessions, we seek to accomplish the following objectives: 1) To provide an international forum for leading basic, translational, and clinical researchers to exchange ideas regarding fundamental concepts contributing to lung inflammation and remodeling. 2) To stimulate interactions between the scientific fields of immunology, pathology, genetics and molecular biology with the goal of identifying emerging, shared interests that may lead to the performance of more efficient and productive research. 3) To enhance the likelihood of success in translation of preclinical scientific advances into direct patient benefit by developing novel strategies to better implement scientific advances into patient care and by addressing challenges in clinical trial design. 4) To challenge and stimulate the scientific interests of trainees, attracting a new generation of junior investigators into the ield of asthma pathobiology.